Evidence map›Paper›PMID 29956027›Full record

ArticleJournal of neurology2018

Prospective study of relevance of

C Alves Do Rego, I J Namer, C Marcel, F Lefebvre, O Lagha-Boukbiza, M Renaud, C Tranchant, M Anheim

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Appropriate assessment method ofJournal of neurology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

C Alves Do RegoDépartement de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
I J NamerDépartement de Biophysique et Médecine Nucléaire, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
C MarcelCabinet de Neurologie, 46 Avenue de Moka, 35400, Saint-Malo, France.
F LefebvreDépartement de Santé Publique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
O Lagha-BoukbizaDépartement de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
M RenaudDépartement de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
C TranchantDépartement de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
M AnheimDépartement de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. mathieu.anheim@chru-strasbourg.fr.
Hôpitaux Universitaires de Strasbourg · FRCentre Hospitalier de Saint-Malo · FRCentre National de la Recherche Scientifique · FRInstitut de génétique et de biologie moléculaire et cellulaire · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

methodsPatients experiencing parkinsonism of ambiguous etiology were clinically classified into the PD group or the MSA group as initial clinical diagnosis (ICD). Then, CGH test and myocardial scintigraphy were performed. Clinical assessment was repeated throughout the disease course until the final clinical diagnosis (FCD) could be established according to the criteria of PD and MSA, respectively.

resultsTwenty-five patients with uncertain diagnosis were included (15 MSA and 10 PD as ICD). At the end of a 6-year follow-up, FCD was MSA in 11/25 patients and PD in 14/25. The CGH test and the scintigraphy showed a sensitivity of 82%, and a specificity of 71 and 93%, respectively, for the diagnosis of MSA. The combination of a normal scintigraphy (i.e., with myocardial MIBG uptake) with genitourinary dysfunction was the most relevant test to diagnose MSA, whereas an abnormal scintigraphy with a levodopa response of > 30% or an abnormal scintigraphy with the absence of OH was the most relevant combinations to diagnose PD. All these combinations had an accuracy superior than 90% and a specificity of 100%.

conclusionCombinations of myocardial scintigraphy with genitourinary dysfunction, levodopa response of > 30%, or orthostatic hypotension could be of interest for the distinction between PD and MSA when the clinical diagnosis remains ambiguous at the first stage of the disease.

Indexed as

Radionuclide Imaging3-IodobenzylguanidineBiomarkersClonidineDiagnosis, DifferentialFemaleFollow-Up StudiesHeartHumansMaleMiddle AgedMultiple System AtrophyParkinson DiseaseProspective StudiesRadiopharmaceuticalsSensitivity and Specificity3-IodobenzylguanidineBiomarkersClonidineRadiopharmaceuticals

Identifiers

PMID29956027
OpenAlexW2810558432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.